[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cardiovascular-cv-risk\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cardiovascular-cv-risk":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,23,0,[8,40,73,105,131,156,184,212,246,269,295,315,344,374,400,431,457,489,514,540,572,598,621],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100625819","prospective-evaluation-of-new-metrics-to-assess-cardiovascular-remodeling-in-obstructive-sleep-apnea-100625819",false,"NCT07427589","Prospective Evaluation of New Metrics to Assess Cardiovascular Remodeling in Obstructive Sleep Apnea","CARDOSA","Inclusion Criteria:\n\n* AHI ≥ 15 events\u002Fhour, based on a recent (\\\u003C2 years) PSG, conducted in Antwerp University Hospital\n* Patients must be 18 years or older\n* Patients must be dutch-speaking\n* Patients must be eligible for their therapy (CPAP, MAD or HNS)\n* Willing to participate after informed consent\n\nExclusion Criteria:\n\n* Central apneas accounting for ≥25% of total apneas during baseline polysomnography\n* Patients who have received effective CPAP therapy (defined as CPAP use for ≥4 h\u002Fnight) within the previous 6 months\n* Patients with prior MAD therapy\n* Uncontrolled hypertension\n* Known cardiomyopathy\n* Significant coronary arterial disease\n* Clinically significant valvular heart disease, defined as more than mild left-sided valvular disease or more than moderate right-sided valvular disease\n* Congenital heart disease\n* Participants may be excluded if, after rescoring, outcome measures do not meet predefined criteria","ALL","18 Years",{"count":19,"type":20},270,"ESTIMATED","1 Year","OBSERVATIONAL","The goal of this prospective study is to gain insight into the endophenotypic variation in OSA, with a focus on the underlying pathophysiological traits and the cardiovascular alterations associated with the condition. To capture the variability in OSA endophenotypes, novel metrics that extend beyond the AHI will be considered, with particular attention to the sleep-apnea-specific hypoxic burden, the sleep-apnea-specific heart rate response, and pulse wave amplitude drops (PWADs). Since the impact of treatment on cardiovascular parameters remains an important point of interest, the effects of different treatment modalities on cardiovascular changes will be investigated, including continuous positive airway pressure (CPAP), mandibular advancement devices (MADs), and hypoglossal nerve stimulation.",[25,26],"Obstructive Sleep Apnea","Cardiovascular (CV) Risk","RECRUITING","2026-06-24",{"date":30,"type":31},"2026-06-29","ACTUAL",{"date":33,"type":31},"2026-06-10",{"date":35,"type":20},"2029-12",{"name":37,"class":38},"University Hospital, Antwerp","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":59,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":4},"100644755","a-two-part-intervention-to-target-cardiovascular-health-100644755","NCT07673172","A Two-Part Intervention to Target Cardiovascular Health","Autism Research Consortium on Physical Health: A Two-Part Intervention to Target Cardiovascular Health","Inclusion Criteria:\n\n* • Have a diagnosis of autism or be told by a healthcare provider that you have autism\n\n  * Be between the ages of 9 and 26\n  * Have a BMI greater than the 84th percentile\n  * English speaking\n\nExclusion Criteria:\n\n* • Children younger than 9 years of age\n\n  * Adults older than 26 years of age\n  * Individuals without a diagnosis of autism\n  * Individuals with a BMI less than the 84th percentile","9 Years","26 Years",{"count":50,"type":20},130,"INTERVENTIONAL",[53],"NA","Obesity is one of the most common health conditions among autistic young people and its prevalence rises at faster rates for autistic-relative to non-autistic-individuals. This places them at heightened risk for cardiovascular disease (CVD) and mortality before they enter adulthood. Studies have identified three key contributing factors to CVD outcomes in autistic individuals: unhealthy lifestyle behaviors, Adverse Childhood Experiences (ACEs), and chronic stress.\n\nThis study will explore the effectiveness of two CVD-focused primary care interventions for autistic individuals (ages 9-26): (1) lifestyle medicine consultations tailored towards supporting health-promoting behaviors; and (2) a Cognitive Behavioral Therapy (CBT) intervention tailored towards addressing chronic stress that contributes to excess weight and maladaptive eating behaviors and results in obesity and CVD. Participants and their caregivers will be randomly placed into either the Lifestyle Medicine Group, CBT Group, or combined Lifestyle Medicine with CBT Group. Participants will respond to questionnaires and surveys measuring lifestyle habits, stress, and psychological risk factors at their first visit, 6-month visit, and 3 months post-intervention visit. Over the course of 6 months, participants will attend virtual sessions (up to three times a month) in accordance with their intervention group.",[56,57,58,26],"Autism","Adverse Childhood Experience","Stress",[60,61,62,63],"autism","adverse childhood experiences","stress","cardiovascular risk","NOT_YET_RECRUITING","2026-06-22",{"date":30,"type":31},{"date":68,"type":20},"2026-07-01",{"date":70,"type":20},"2028-08-31",{"name":72,"class":38},"University of California, Los Angeles",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":80,"sex":81,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":86,"conditions":87,"keywords":88,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":39},"100363602","geospatial-analysis-of-neighborhood-environmental-stress-in-relation-to-biological-markers-of-cardiovascular-health-and-health-behaviors-in-women-100363602","NCT04014348","Geospatial Analysis of Neighborhood Environmental Stress in Relation to Biological Markers of Cardiovascular Health and Health Behaviors in Women","Pilot Study for Geospatial Analysis of Neighborhood Environmental Stress in Relation to Biological Markers of Cardiovascular Health and Health Behaviors in Women","* INCLUSION CRITERIA:\n\nIndividuals eligible for this protocol:\n\n1. A healthy self-identified White female (i.e. self-identifies as White or of European descent) or healthy Black female (i.e. self-identifies as Black, African American, or of African descent)\n2. Must be between 19 to 45 years of age\n3. Must not have any chronic health condition (i.e.: cardiovascular, autoimmune, endocrinologic), or active infection\n4. Must be living in Washington, DC\n5. Must have access to a smartphone\n6. Must be able to provide informed consent\n7. Must speak English.\n\nEXCLUSION CRITERIA:\n\n1. Pregnant or breast feeding\n2. Physically unable to perform physical activity for any reason\n3. Subject had weight changes greater than 20% over the past 3 months\n4. Subject is obese by our measurements (BMI greater than or equal to 35.0 kg\u002Fm\\^2)\n5. If you have high or low blood pressure requiring medications\n6. Diabetes\n7. History of severe mental illnesses, treated with hospitalization\n8. If you have evidence of active thyroid disease requiring medications\n9. If you are taking medication for chronic non-mental health related illness (ie: cardiovascular, autoimmune, endocrinologic)\n10. If you have food allergies or highly restrictive diets that may prevent your ability to consume a controlled metabolic diet.\n11. If you are a current smoker (tobacco products)",true,"FEMALE","19 Years","45 Years",{"count":85,"type":20},250,"Background:\n\nHeart disease is a leading cause of death in the United States. Healthy diet and exercise improve heart health. Some features of where a person lives can lead to stress and decrease chances for exercise. Researchers want to see how these factors may increase the risk of heart disease in women.\n\nObjective:\n\nTo see if there are differences in stress levels between women who live in different parts of Washington, DC. Also, to see how these women use their neighborhoods for exercise.\n\nEligibility:\n\nHealthy white or black females ages 19-45 who live in Washington, DC, who have access to a smartphone\n\nDesign:\n\nParticipants may stay at the NIH Clinical Center overnight for a 2-day visit.\n\nVisit 1 will include:\n\nPhysical exam\n\nBlood tests\n\nElectrocardiogram: Electrodes on the participant s skin will measure heart activity.\n\nPET\u002FCT scan: Participants will get an injection. They will lie in a machine that takes pictures of the body.\n\nSurveys\n\nBody size measurements\n\nNutrition consultation\n\nBlood vessel tests: This is measured with blood pressure cuffs, a device placed on the participant s fingertip, and a probe placed on the participant s neck.\n\nResting Energy Expenditure: Participants will breathe under a clear hood for 45 minutes.\n\nParticipants will be followed for about 2 weeks. They will wear a device on the wrist and carry a GPS device. Through a mobile app, they will answer short daily surveys on stress and exercise.\n\nVisit 2-\n\nDevice return\n\nNutritional consultation",[26],[89,90,91,92,93,94],"Neighborhood Environment","Cardiovascular Disease Risk","Social Determinants of Health","Diagnostic Behavioral study","Socio-Economic","Natural History","2026-06-04",{"date":97,"type":31},"2026-06-05",{"date":99,"type":31},"2021-10-20",{"date":101,"type":20},"2026-12-26",{"name":103,"class":104},"National Heart, Lung, and Blood Institute (NHLBI)","NIH",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":80,"sex":16,"minAge":112,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":51,"phases":115,"briefSummary":116,"conditions":117,"keywords":118,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":4},"100637757","democratizing-access-to-cleaner-residential-air-100637757","NCT07629518","Democratizing Access to Cleaner Residential Air","DACRA","Inclusion Criteria:\n\nAge 40 years or older Speaks English, Vietnamese, and\u002For Chinese Cognitive capacity to respond to questionnaires Lives fulltime at the current address, adjacent (\\\u003C 200 meters) to roadways with large traffic volumes Must have one or more risk factors (hypertension or elevated blood pressure, pre-diabetes or diabetes or elevated blood sugar levels, elevated cholesterol levels, body mass index 25 or greater)\n\nExclusion Criteria:\n\nPregnant Works between the hours of 10 PM and 6 AM Sources of smoke in the living space (such as candles, incense, marijuana, wood stove, fireplace) almost every day\u002Fevery day.\n\nEvery day exposure to motor vehicle exhaust (from cars, trucks, buses, trains), including heavy street or highway traffic.\n\nCurrently smoking or vaping Others smoking or vaping indoors, in the living space. Within the past 5 years, a diagnosis of heart attack, heart disease, stroke, blood clots or pulmonary embolism, cancer requiring surgery and\u002For chemo\u002Fradiation therapy","40 Years",{"count":114,"type":20},66,[53],"The purpose of this research study is to determine whether the use of in-home air filtration to reduce exposure to air pollution benefits health.",[26],[119,120,121,63,122],"air pollution","air purifiers","HEPA filtration","biomarkers","2026-06-01",{"date":97,"type":31},{"date":126,"type":20},"2026-09",{"date":128,"type":20},"2029-05",{"name":130,"class":38},"Douglas Brugge",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":16,"minAge":112,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":51,"phases":141,"briefSummary":142,"conditions":143,"keywords":144,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":39},"100638150","cardiovascular-prevention-supported-by-digital-technology-comparison-with-the-traditional-model-100638150","NCT07608926","Cardiovascular Prevention Supported by Digital Technology: Comparison With the Traditional Model","DIGITAL PREV","Inclusion Criteria:\n\n* Age between 40 and 75 years\n* hypertension\n* hyperglycaemia\n* type 2 diabetes not requiring insulin therapy\n* dyslipidaemia\n* active smoking\n* overweight\u002Fgrade I obesity\n* Willingness to participate in follow-up visits over 24 months\n\nExclusion Criteria:\n\n* previous myocardial infarction\n* stroke\n* transient ischemic attack\n* coronary artery diseas\n* peripheral arterial occlusive disease\n* heart failure\n* Type 1 or type 2 diabetes mellitus on insulin therapy\n* Advanced chronic kidney disease (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²)\n* Active cancer disease\n* Severe obesity\n* Inability to use digital tools\n* Pregnancy","75 Years",{"count":140,"type":20},144,[53],"Cardiovascular diseases represent one of the leading causes of morbidity and mortality worldwide. Prevention in patients at cardiovascular risk is essential to reduce the incidence of cardiovascular events and slow the progression of risk.\n\nThis study aims to evaluate the effectiveness and feasibility of a cardiovascular prevention pathway delivered remotely through a digital application, comparing it with a traditional in-person care pathway.",[26],[145,146],"Cardiovascular risk factors","Prevention","2026-05-19",{"date":149,"type":31},"2026-05-27",{"date":151,"type":31},"2025-05-28",{"date":153,"type":20},"2028-06",{"name":155,"class":38},"Maria Cecilia Hospital",{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":80,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":51,"phases":166,"briefSummary":167,"conditions":168,"keywords":172,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":181,"locationsCount":183},"100598123","improving-the-heart-health-of-home-health-aides-100598123","NCT07067398","Improving the Heart Health of Home Health Aides","Improving the Cardiovascular Health of Home Health Aides","VITAL","Inclusion Criteria:\n\n* Currently working as a home health aide\n* Speak English or Spanish\n* ≥ 18 years of age\n* Have low CV Health as assessed by LE8 components made up by physical health measurements (blood pressure, BMI) and general self-reported health (physical activity, diet, smoking, sleep); calculated to be a score of 0-50 (the total score ranges from 0-100)\n\nExclusion Criteria:\n\n* Less than 1 year of job experience as a home health aide\n* Does not possess a smartphone\n* Gotten dizzy before with a finger stick blood sugar\u002Fcholesterol test\n* Have a history of syncope with a finger stick blood sugar\u002Fcholesterol test",{"count":165,"type":20},40,[53],"The goal of this early-stage study is to support the heart health of home health aides, a workforce that provides care for adults at home but whose own health has been historically poor. To do this, the study will use Life's Essential 8 (LE8), a program developed by the American Heart Association (AHA) that promotes cardiovascular wellness through education and lifestyle changes. The program has been adapted specifically for home health aides and will be delivered by trained \"peer coaches,\" who are fellow home health aides who will help guide participants through the program.\n\nThe main questions the study aims to answer are:\n\n* Will the LE8 intervention, which provides cardiovascular health education and support with positive thinking, be used by home health aides and do they like it?\n* Does the LE8 intervention actually improve home health aides' cardiovascular health after the intervention's conclusion compared to baseline?\n\nParticipants will be paired with a trained peer coach and take part in the 10-week program over the course of 6 months. The program includes support for healthy behaviors and positive thinking, with the goal of making lasting improvements in cardiovascular health.",[169,26,170,171],"Cardiovascular","Cardiovascular Disease (CVD) Risk Factors","Cardiovascular Health",[173,174,175],"cardiovascular health intervention","home health aide","peer coaching",{"date":177,"type":31},"2026-05-22",{"date":179,"type":31},"2025-09-09",{"date":126,"type":20},{"name":182,"class":38},"Weill Medical College of Cornell University",2,{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":80,"sex":16,"minAge":191,"maxAge":192,"enrollmentInfo":193,"targetDuration":4,"studyType":51,"phases":195,"briefSummary":196,"conditions":197,"keywords":198,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":210,"locationsCount":4},"100638762","cardiometabolic-effects-of-low-fat-and-full-fat-dairy-100638762","NCT07605442","Cardiometabolic Effects of Low-Fat and Full-Fat Dairy","Cardiometabolic Effects of Low-Fat and Full-Fat Dairy in Healthy and Cardiometabolically At-Risk Adults","Inclusion Criteria:\n\n* BMI 18.5 to 39.9 kg\u002Fm2\n* LDL-C ≤190 mg\u002FdL assessed by the Modified Sampson-NIH Equation\n* Currently consume milk, yogurt, and\u002For cheese daily\n* Willing to eat 3 servings of dairy (milk, yogurt, cheese) for two 6-week periods during the study\n\nExclusion Criteria:\n\n* Hemoglobin \\\u003C13.2 g\u002FdL for men or \\\u003C 11.7 g\u002FdL for women at screening\n* Fasting triglycerides \\>350 mg\u002FdL at screening\n* ≥10% change in body weight within the 6 months prior to enrollment\n* Blood pressure \\>140\u002F90 mmHg at screening\n* Fasting glucose ≥126 mg\u002FdL\n* Type 1 or type 2 diabetes\n* Takes any (prescription or over-the-counter) anti-hypertensive, lipid-lowering, glucose-lowering or anti-inflammatory drugs, or drugs that alter body weight\n* Intake of supplements that affect the outcomes of interest (i.e., lipids, blood pressure, glucose, body weight, inflammation and microbiome) and are unwilling to cease during the study period.\n* Unwilling to refrain from starting to take any supplements, vitamins, nutritional products, or health foods that are not prescribed by a doctor for the duration of the study\n* History of liver, kidney, or autoimmune disease\n* Prior cardiovascular event (e.g., stroke, heart attack)\n* Current pregnancy or intention of pregnancy within the next 12 months\n* Lactation within the prior 6 months\n* Dairy allergy\u002Fintolerance\u002Fsensitivity\u002Fdislike\n* Antibiotic use within the prior four weeks\n* Oral steroid use within the prior four weeks\n* Use of tobacco or nicotine-containing products within the past 6 months\n* History of cancer at any site within the past 10 years (eligible if ≥10 years without recurrence) or non-melanoma skin cancer within the past 5 years (eligible if ≥5 years without recurrence)\n* Participation in another clinical trial within 60 days of baseline\n* Currently following a restricted or weight-loss diet\n* Prior bariatric surgery\n* Intake of \\>14 alcoholic drinks\u002Fweek and\u002For not willing to avoid alcohol consumption for 48 hours prior to test visits\n* Does not speak and\u002For understand English\n* Unwilling to refrain from donating blood and\u002For plasma during the study\n* Weight \\\u003C110 lb\n* Lactose intolerance or sensitivity\n* Unwilling to contact study staff before enrolling in other health-related research and avoid participating in any research that may interfere with this study\n* For individuals taking thyroid medication: abnormal thyroid stimulated hormone (TSH) concentration, or change in dose of thyroid medication within the last 6 months\n* Principal Investigator discretion related to the potential participant's ability to adhere to the study requirements, including being able to come to attend visits","25 Years","70 Years",{"count":194,"type":20},178,[53],"The purpose of this study is to find out if full-fat dairy and low-fat dairy have similar effects on risk factors for heart disease and diabetes. During the study, participants will consume two types of dairy products: low-fat dairy (milk, yogurt, and cheese) and full-fat dairy (milk, yogurt, and cheese). Each type of dairy will be consumed for 6 weeks with a ≥4-week break between. Measures will be taken to evaluate blood cholesterol, blood sugar, body weight, inflammation, blood pressure, heart health and dietary intake at the beginning and end of each 6 week period.",[26],[199,200,201,202,203],"dairy","diet","nutrition","LDL-cholesterol","cardiovascular disease","2026-05-18",{"date":206,"type":31},"2026-05-26",{"date":208,"type":20},"2026-09-08",{"date":70,"type":20},{"name":211,"class":38},"Penn State University",{"id":213,"slug":214,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":218,"eligibilityCriteria":219,"healthyVolunteers":11,"sex":16,"minAge":83,"maxAge":4,"enrollmentInfo":220,"targetDuration":4,"studyType":51,"phases":222,"briefSummary":224,"conditions":225,"keywords":231,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":39},"100605891","phase-4-landiolol-to-avoid-tachycardia-in-patients-at-risk-for-cardiovascular-events-undergoing-major-non-cardiac-surgery-100605891","NCT07168421","LANdiolol to Avoid TAchycardia in Patients at Risk for Cardiovascular Events Undergoing Major Non-cardiac Surgery","LANdiolol to Avoid TAchycardia in Patients at Risk for Cardiovascular Events Undergoing Major Non-cardiac Surgery: a Feasibility Trial","LANTA-P","Inclusion Criteria:\n\n* Patients undergoing elective non-cardiac surgery defined as intermediate or high-risk by the 2022 european society of cardiology (ESC) guidelines\n* surgery performed under general anesthesia;\n* expected length of hospital stay ≥ 24 hours;\n* age ≥ 45 years;\n* at least two of the following risk factors:\n\n  * age ≥ 75 years\n  * arterial hypertension;\n  * ischemic heart disease (history of myocardial infarction or positive exercise test, current complaint of chest pain considered to be secondary to myocardial ischemia, use of nitrates, pathological Q waves, prior coronary revascularization);\n  * history of congestive heart failure;\n  * history of cerebrovascular disease;\n  * peripheral artery disease;\n  * diabetes mellitus;\n  * GFR ≤ 59 ml\u002Fmin pro 1.73 m2;\n  * pre-operative NTproBNP \\> 200 pg\u002Fml;\n* excessive sympathetic outflow as proven by exercise testing:\n\n  * impaired heart rate recovery (≤ 12 bpm within 1 minute after cessation of exercise); OR\n  * exaggerated heart rate response (≥ 12 bpm after 3 minutes of unloaded pedalling);\n\nExclusion Criteria:\n\n* unable to consent or follow study procedures;\n* absolute contraindications for exercise testing;\n* pregnancy or intention to become pregnant;\n* active cardiac conditions (such as unstable coronary syndromes, decompensated heart failure, significant arrhythmias, severe valvular disease);\n* urgent \u002F emergency surgery;\n* already on β-blocker (within the last 30 days prior to recruitment);\n* contraindication for β-blocker therapy (bradycardia (HR \\\u003C 55 bpm), hypotension (systolic blood pressure \\\u003C 100 mmHg), severe peripheral vascular disease, severe asthma, allergy, higher-degree atrioventricular block);\n* severe preoperative anaemia (haemoglobin \\\u003C 100 g\u002FL) unless there is a plan set up and followed for correction prior to surgery;\n* planned intermediate care or intensive care admission;\n* prior enrolment in this trial.",{"count":221,"type":20},114,[223],"PHASE4","Limiting perioperative tachycardia (aiming for a heart rate \\\u003C90 beats per minute throughout the perioperative period) using the ultra-short acting beta-blocker landiolol in patients with cardiovascular risk factors undergoing major surgery might lower the incidence of perioperative myocardial injury. Feasibility of the intervention needs to be proven prior to conduction of a larger trial.",[226,227,26,228,229,230],"Perioperative Myocardial Injury","Autonomic Dysfunction","Major Surgery","Beta Blocker","Myocardial Injury After Non-cardiac Surgery",[232,233,234,235,236],"perioperative myocardial injury","major surgery","beta blocker","myocardial injury after non-cardiac surgery","autonomic dysfunction","2026-05-04",{"date":239,"type":31},"2026-05-05",{"date":241,"type":31},"2026-04-24",{"date":243,"type":20},"2028-03-01",{"name":245,"class":38},"Insel Gruppe AG, University Hospital Bern",{"id":247,"slug":248,"hasResults":11,"nctId":249,"briefTitle":250,"officialTitle":250,"acronym":4,"eligibilityCriteria":251,"healthyVolunteers":11,"sex":81,"minAge":17,"maxAge":4,"enrollmentInfo":252,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":254,"conditions":255,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":39},"100614783","the-synergistic-effects-of-menopause-and-hiv-on-cardiovascular-disease-risk-in-women-100614783","NCT07284082","The Synergistic Effects of Menopause and HIV on Cardiovascular Disease Risk in Women","Inclusion Criteria:\n\n* 90 non-pregnant women with HIV (approximately 30 in each menopausal phase) from the San Francisco MWCCS site.\n\nExclusion Criteria:\n\n* Women who are not virally suppressed (HIV RNA \\>200 copies\u002FmL)\n* Women who are not on antiretroviral therapy\n* Women who have a history of hysterectomy or oophorectomy\n* Women who are receiving treatment for active cancer or tuberculosis",{"count":253,"type":20},90,"Menopause is associated with the acceleration of many comorbidities, including cardiovascular disease. Whether HIV and menopause together increase cardiovascular disease risk is a key knowledge gap. The goal of this observational study is to address this knowledge gap by looking at the role of menopause on cardiovascular disease risk factors such as insulin resistance, hypertension, hyperlipidemia, and carotid atherosclerosis using previously collected data. The investigators will look at underlying causes for cardiovascular diseases worsening in menopausal women with HIV by looking at the role of increased inflammation in the body and whether this is altered by weight. The investigators achieve this by enrolling participants who are willing to undergo a whole body MRI.",[256,257,26,258,259],"HIV","Menopause","Carotid Arteriosclerosis","Body Composition","2026-04-20",{"date":262,"type":31},"2026-04-22",{"date":264,"type":31},"2026-04-17",{"date":266,"type":20},"2030-03-01",{"name":268,"class":38},"University of California, San Francisco",{"id":270,"slug":271,"hasResults":11,"nctId":272,"briefTitle":273,"officialTitle":274,"acronym":275,"eligibilityCriteria":276,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":138,"enrollmentInfo":277,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":279,"conditions":280,"keywords":283,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":290,"completionDateStruct":291,"leadSponsor":293,"locationsCount":39},"100634873","integrated-ultrasound-derived-fat-fraction-and-2d4d-heartai-for-cardiovascular-risk-management-in-patients-with-masld-100634873","NCT07545343","Integrated Ultrasound-Derived Fat Fraction and 2D\u002F4D HeartAI for Cardiovascular Risk Management in Patients With MASLD","Integration of Ultrasound-Derived Fat Fraction With 2D and 4D HeartAI for Cardiovascular Risk Management in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Prospective Observational Cohort Study","MUCHAI","Inclusion Criteria:\n\n* Adults aged 18 to 75 years\n* Diagnosis of MASLD based on imaging or biopsy\n* Presence of at least one cardiometabolic risk factor, such as BMI ≥25 kg\u002Fm², type 2 diabetes mellitus, or dyslipidemia\n* No contraindication to ultrasound imaging\n\nExclusion Criteria:\n\n* Significant alcohol consumption: \\>20 g\u002Fday for women or \\>30 g\u002Fday for men Secondary causes of hepatic steatosis, such as viral hepatitis or autoimmune liver disease\n* Known advanced heart failure (New York Heart Association class III-IV)\n* Recent cardiovascular event within 6 months\n* Pregnancy\n* Inability to complete follow-up",{"count":278,"type":20},700,"This prospective observational cohort study aims to evaluate the association between liver fat fraction measured by ultrasound-derived fat fraction (UDFF) and cardiac functional parameters assessed by 2D and 4D HeartAI in adult patients with metabolic dysfunction-associated steatotic liver disease (MASLD). Participants will undergo baseline assessment and repeat evaluations at 6, 12, and 36 months. The study will assess the diagnostic performance of integrated UDFF-HeartAI analysis for detecting subclinical cardiac abnormalities and identify predictors of cardiovascular risk progression and major adverse cardiovascular events in patients with MASLD.",[281,26,282],"MASLD","Subclinical Cardiovascular Impairments",[284,285,286,287],"Ultrasound-Derived Fat Fraction","Echocardiography","Cardiovascular Events","Major Adverse Cardiovascular Events","2026-04-16",{"date":262,"type":31},{"date":123,"type":20},{"date":292,"type":20},"2030-05-31",{"name":294,"class":38},"First Affiliated Hospital, Sun Yat-Sen University",{"id":296,"slug":297,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":299,"acronym":4,"eligibilityCriteria":300,"healthyVolunteers":80,"sex":16,"minAge":301,"maxAge":4,"enrollmentInfo":302,"targetDuration":4,"studyType":51,"phases":304,"briefSummary":305,"conditions":306,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":39},"100604274","lions-hearts-a-community-approach-to-multigenerational-cardiovascular-disease-risk-100604274","NCT07147387","Lions Hearts: A Community Approach to Multigenerational Cardiovascular Disease Risk","Inclusion Criteria:\n\n* Mother-child dyad willing to participate together in the full 12-week intervention and assessment activities\n* Child aged 10-17 years old\n* Mother (or female caregiver)\n* Both mother and child must be able to safely engage in moderate-to-vigorous physical activity, as determined by pre-participation health screening (e.g., PAR-Q+)\n* Access to transportation to attend twice-weekly exercise sessions at a local CrossFit affiliate\n\nExclusion Criteria:\n\n* Presence of a medical condition that would make participation in moderate-to-vigorous physical activity unsafe, as determined by health screening or medical provider (e.g., uncontrolled hypertension, cardiovascular disease, severe orthopedic limitations)","10 Years",{"count":303,"type":20},100,[53],"This pilot study evaluates the feasibility, acceptability, and preliminary effectiveness of Lion Hearts, a community-based, family-centered physical activity intervention designed to improve cardiovascular health among mother-child dyads. Developed through community co-design, the 12-week intervention is delivered in local CrossFit affiliates and includes twice-weekly fitness sessions incorporating functional movement, goal setting, teamwork, and health education. The study aims to assess changes in physical activity, fitness, and cardiovascular health markers, as well as family dynamics and motivation for physical activity. Participants complete baseline, mid-, post-, and 3-month follow-up assessments, including surveys, fitness testing, accelerometry, and optional lab work. Findings will inform the refinement of the intervention for future large-scale trials.",[26],"2026-04-01",{"date":309,"type":31},"2026-04-02",{"date":311,"type":20},"2026-08-01",{"date":313,"type":20},"2027-12-01",{"name":211,"class":38},{"id":316,"slug":317,"hasResults":11,"nctId":318,"briefTitle":319,"officialTitle":319,"acronym":320,"eligibilityCriteria":321,"healthyVolunteers":11,"sex":16,"minAge":322,"maxAge":4,"enrollmentInfo":323,"targetDuration":4,"studyType":51,"phases":324,"briefSummary":325,"conditions":326,"keywords":330,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":336,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":342,"locationsCount":39},"100629045","effects-of-an-aerobic-exercise-program-on-cardiovascular-risk-in-patients-with-chronic-kidney-disease-or-rheumatoid-arthritis-100629045","NCT07469540","Effects of an Aerobic Exercise Program on Cardiovascular Risk in Patients With Chronic Kidney Disease or Rheumatoid Arthritis","PARCA","Inclusion Criteria:\n\n* Diagnosis of Chronic Kidney Disease (CKD) or Rheumatoid Arthritis (RA), with no other risk factors related to the disease.\n* Having a glomerular filtration rate between 45 and 20 ml\u002Fmin\u002F1.73 m², corresponding to stages III and IV not on dialysis for patients with CKD ; or have a DAS 28 score ≥ 2.6 points for patients with RA.\n* Have a medical certificate stating that there are no adverse reactions to physical activity.\n* Affiliation with a French social security scheme or beneficiary of such a scheme.\n\nExclusion Criteria:\n\n* Unstabilised corticosteroid therapy and\u002For \\>10mg prednisone\u002Fday\n* Uncontrolled high blood pressure\n* Pregnant women\n* Impaired higher functions making it impossible to understand and adhere to an aerobic exercise program\n* Inability to perform physical exercise, regardless of the cause (neurological, central or peripheral, cardiovascular or respiratory, or musculoskeletal)\n* Legal incapacity or limited legal capacity\n* Subject unlikely to cooperate with the study and\u002For low cooperation anticipated by the investigator\n* Subject without health insurance\n* Subject is in the exclusion period of another study involving human subjects that may interfere with the results of this study, particularly by affecting inflammatory status and the cardiovascular system.","50 Years",{"count":253,"type":20},[53],"The goal of this clinical trial is to determine whether an aerobic exercise program can reduce cardiovascular risk in patients with systemic inflammation, such as those with rheumatoid arthritis and chronic kidney disease.\n\nThe main questions this study aims to address are:\n\n* Does an individualized aerobic exercise program reduce cardiovascular risk, as assessed arterial stiffness and endothelial function ?\n* What are the effects of this exercise program on inflammation and immunosenescence?\n\nResearchers will compare an individualized aerobic exercise program with a therapeutic education program (consisting of educational phone calls only) and a control group with no intervention.\n\nParticipants will:\n\n* Perform three physical activity sessions per week for six weeks (45-minute sessions at 60-80% of heart rate reserve);\n* Attend clinic visits at baseline, after the 6-week intervention, and at a 6-week follow-up after the intervention;\n* Undergo assessments including pulse wave velocity, hyperemic reactivity, and blood analyses.",[327,328,329,26],"Aerobic Exercise","Rhumatoid Arthisis","Chronic Kidney Disease",[331,332,333,334],"Systemic Inflammation","Arterial Stiffness","Hyperemic reactivity","Blood analyses","2026-03-10",{"date":337,"type":31},"2026-03-13",{"date":339,"type":20},"2026-03-16",{"date":341,"type":20},"2026-12-31",{"name":343,"class":38},"Jérôme Bouchan",{"id":345,"slug":346,"hasResults":11,"nctId":347,"briefTitle":348,"officialTitle":349,"acronym":350,"eligibilityCriteria":351,"healthyVolunteers":80,"sex":16,"minAge":352,"maxAge":353,"enrollmentInfo":354,"targetDuration":4,"studyType":51,"phases":356,"briefSummary":357,"conditions":358,"keywords":361,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":367,"startDateStruct":369,"completionDateStruct":370,"leadSponsor":372,"locationsCount":39},"100626778","physical-inactivity-among-patients-with-cardiovascular-risk-100626778","NCT07440056","Physical Inactivity Among Patients With Cardiovascular Risk","Physical Inactivity Among Patients With Cardiovascular Risk: Proportion, Associated Factors, Perceived Barriers, and Effectiveness of an Intervention for Improvement at Government Primary Medical Care Institutions in Gampaha District","INSPIRE-PA","Inclusion Criteria:\n\n1. Patients permanently residing in Gampaha district for six months or more\n2. Patients registered and followed up at medical clinics in the same state sector PMCIs in Gampaha district, for a duration of three months or more\n\nExclusion Criteria:\n\n1. Pregnant mothers with any intermediate risk factor of chronic NCDs, followed up at state PMCIs in Gampaha district\n2. Patients diagnosed with atherosclerotic cardiovascular disease (ASCVD) (e.g. Coronary heart disease, Cerebrovascular disease, Peripheral artery disease, Aortic atherosclerotic disease) followed up at state sector primary medical care institutions in Gampaha district.\n3. Patients already diagnosed and on treatment for diabetes mellitus, any type of cancer and any chronic respiratory disease (e.g. Asthma, chronic obstructive pulmonary disease) followed up at state sector primary medical care institutions in Gampaha district, as their physical activity level and their knowledge on it may have changed following the diagnosis\n4. Patients with impaired cognitive functions (confirmed with medical records), as they are unable to report accurate responses independently.\n5. Patients who have undergone any surgical procedure within the last three months (confirmed by clinical documentation)\n6. Patients who have had any debilitating illness during the preceding week limiting their physical activity during the period of illness\n7. Patients who plan to change\u002Fchange their place of residence or shift their treatment follow-up from a state-sector PMCI to the private sector or any other treatment modality (e.g: Ayurveda) within the next six months","35 Years","65 Years",{"count":355,"type":20},192,[53],"The goal of this clinical trial is to learn if newly developed intervention package works to improve physical activity level among patients with intermediate cardiovascular risk factors. The main questions it aims to answer are:\n\nDoes the INSPIRE-PA intervention increase the level of physical activity among participants with intermediate cardiovascular risk factors?\n\n* What changes occur in physical activity level, BMI and blood pressure following participation in the intervention?\n* Are there any challenges, barriers, or unintended effects experienced by participants during the intervention period?\n* Researchers will compare the INSPIRE-PA intervention to usual care to determine whether the empowerment-based strategy is effective in improving physical activity levels and reducing cardiovascular risk among patients attending government primary medical care Iinstitutions.\n\nParticipants will:\n\n* Participate in the INSPIRE-PA program for 6 months\n* Attend scheduled follow-up visits at the primary medical care institution (e.g., every 2-4 weeks)for counselling, evaluation of physical activity level, and assessment of cardiovascular risk indicators\n* Engage in structured physical activity as recommended in the intervention package\n* Record their daily physical activity and any challenges or barriers in a physical activity logbook or diary\n* Undergo periodic measurements such as blood pressure, weight, waist circumference, and other relevant clinical assessments",[359,26,360],"Physical Activities","Empowerment",[362,363,364,365],"Physical activity","primary care","behavioural intervention","level of physical activity improvement","2026-02-24",{"date":368,"type":31},"2026-02-27",{"date":307,"type":20},{"date":371,"type":20},"2026-09-30",{"name":373,"class":38},"University of Colombo",{"id":375,"slug":376,"hasResults":11,"nctId":377,"briefTitle":378,"officialTitle":378,"acronym":379,"eligibilityCriteria":380,"healthyVolunteers":80,"sex":16,"minAge":83,"maxAge":4,"enrollmentInfo":381,"targetDuration":4,"studyType":51,"phases":383,"briefSummary":384,"conditions":385,"keywords":386,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":391,"lastUpdatePostDateStruct":392,"startDateStruct":394,"completionDateStruct":396,"leadSponsor":398,"locationsCount":4},"100623951","the-effect-of-water-physical-exercise-program-in-thermal-water-and-hydropinotherapy-on-cardiovascular-health-100623951","NCT07403305","The Effect of Water Physical Exercise Program in Thermal Water and Hydropinotherapy on Cardiovascular Health","WPEPH","Inclusion Criteria:\n\n* Men or women\n* Age: \\>45 years\n* Written informed consent prior to participation\n* Physical condition suitable for participating in physical exercise activities\n* Controlled health conditions\n\nExclusion Criteria:\n\n* History of chronic or severe diseases that may affect study outcomes or limit study participation, such as:\n* Decompensated cardiovascular disease, renal insufficiency, or severe liver disease\n* Conditions preventing the ability in physical activity (e.g., severe respiratory issues, reduced mobility, severe arthritis)\n* Severe psychiatric or cognitive disorders that could affect comprehension or adherence to the study\n* Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or corticosteroids\n* Pregnancy or lactation\n* Less than 80% attendance at the 16-week aquatic exercise program",{"count":382,"type":20},80,[53],"The goal of this randomized four-arm clinical trial is to determine the effect of 16-week water physical exercise program in thermal water and hydroponotherapy on lipide profile in middle-aged and elderly people, with controlled health conditions.\n\nParticipants will be randomizate into four arms:\n\n* Arm I: Control\n* Arm II: Water Physical Exercise Program (WPEP) in thermal water\n* Arm III: Hydropinotherapy with thermal water combined with bay leaf (L. nobilis)\n* Arm IV: WPEP in thermal water and hydropinotherapy with thermal water combined with bay leaf (L. nobilis)\n\nPrimary outcome:\n\n1. Lipid profile (cholesterol total, low-density lipoprotein cholesterol (c-LDL), high-density lipoprotein cholesterol (c-HDL), triglycerides)\n\n   Secondary parameters:\n2. Inflammatory biomarkers: interleukin-6 (IL-6), C-reactive protein (CRP)\n3. Glucose metabolisc: fasting plasma glucose, insulin, Hemoglobin A1c (HbA1c)\n4. Aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase, bilirubin, creatinine.\n5. Anthropometric and clinical variables: weight, waist to hip ratio, body composition and bone mineral density\n6. Systolic and diastolic blood pressure\n7. Physical function\n8. Lifestyle parameters: sleep quality, quality of life and eating habits",[26],[387,388,389,390,171],"Thermal Water","Water Exercise","Hydropinotherapy","Lipid Profile","2026-02-04",{"date":393,"type":31},"2026-02-11",{"date":395,"type":20},"2026-01-19",{"date":397,"type":20},"2026-10-31",{"name":399,"class":38},"Instituto Politécnico de Bragança",{"id":401,"slug":402,"hasResults":11,"nctId":403,"briefTitle":404,"officialTitle":405,"acronym":406,"eligibilityCriteria":407,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":138,"enrollmentInfo":408,"targetDuration":4,"studyType":51,"phases":409,"briefSummary":410,"conditions":411,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":423,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":429,"locationsCount":4},"100621936","effects-of-sweetener-consumption-on-risk-factors-for-heart-disease-in-prediabetic-subjects-100621936","NCT07377097","Effects of Sweetener Consumption on Risk Factors for Heart Disease in Prediabetic Subjects","Effects of Sweetener Consumption on Risk Factors for Heart Disease","Sweetheart","Inclusion Criteria:\n\n* Presence of prediabetes (HbA1c 5.7-6.4% or glucose after oral glucose tolerance test 140 to 199 mg\u002FdL)\n* Written informed consent available\n\nExclusion Criteria:\n\n* Inability to communicate sufficiently in the required language\n* Dementia or other significantly cognitively impairing condition\n* Current pregnancy or breastfeeding\n* Other severe internal, neurological, or psychiatric condition\n* History of gout\n* History of gallstones \u002F diagnosis of cholelithiasis",{"count":382,"type":20},[53],"The aim of this prospective interventional study is to investigate the metabolic effects of consuming artificial and natural sweeteners in persons with prediabetes. Prediabetes is a condition characterized by blood sugar levels that are elevated above normal but not yet meeting the criteria for type 2 diabetes. This condition markedly increases the risk of progressing to type 2 diabetes, which in turn can lead to complications including cardiovascular diseases.\n\nArtificial sweeteners such as saccharin and sucralose, as well as natural sugar substitutes like erythritol, are increasingly used as alternatives to sugar and are recommended for individuals at cardiometabolic risk - including overweight individuals, patients with prediabetes, or diabetics - to help reduce caloric intake. Recent literature has reported possible negative associations between artificial sweeteners and blood sugar regulation in healthy subjects (1). Additionally, effects on various blood cells have been observed. For example, erythritol has been shown to alter platelet function leading to increased reactivity in healthy study participants following consumption (2).\n\nHowever, the impact of alternative sweeteners on metabolic processes and their effects on blood coagulation in patients with prediabetes-a population at increased risk-has not been systematically studied. In this planned interventional study, 80 patients meeting laboratory criteria for prediabetes will be randomly assigned to one of four groups, each receiving a different intervention for two weeks: saccharin, sucralose, erythritol, or a control group receiving water. The doses reflect the acceptable daily intake or known doses that are considered safe.\n\nAfter enrollment, participants will visit the study center 2 times: before starting the intervention and after completing the intervention. During these visits, biological samples such as blood, urine, and stool will be collected to study metabolism, gut bacteria, immune and blood cell function. Tests will include an oral glucose tolerance test, coagulation tests, and additional blood analyses. Additionally, participants will wear a glucose monitor to track blood sugar fluctuations during the intervention.\n\nThe investigators hypothesize that consumption of alternative sweeteners negatively affects blood sugar regulation and insulin sensitivity in patients with prediabetes. Furthermore, this study will explore how the candidate sweeteners influence the gut microbiome, blood cells and other metabolic factors in this population.",[412,413,414,415,416,26,417,418,419,420,421],"Prediabetic State","Metabolic Syndrome","Insulin Resistance","Thrombosis","Hypercoagulable State","Cardiovascular Risk Factors","Cardiovascular Diseases (CVD)","Prediabetes","Prediabetes \u002F Type 2 Diabetes","Sweeteners","2026-01-22",{"date":424,"type":31},"2026-01-29",{"date":426,"type":20},"2026-01-05",{"date":428,"type":20},"2026-11-01",{"name":430,"class":38},"Charite University, Berlin, Germany",{"id":432,"slug":433,"hasResults":11,"nctId":434,"briefTitle":435,"officialTitle":435,"acronym":436,"eligibilityCriteria":437,"healthyVolunteers":80,"sex":81,"minAge":17,"maxAge":4,"enrollmentInfo":438,"targetDuration":440,"studyType":22,"phases":4,"briefSummary":441,"conditions":442,"keywords":445,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":449,"lastUpdatePostDateStruct":450,"startDateStruct":452,"completionDateStruct":454,"leadSponsor":455,"locationsCount":39},"100620376","cardiovascular-risk-assessment-in-young-women-after-index-pregnancy-with-and-without-placental-complications-100620376","NCT07356817","Cardiovascular Risk Assessment in Young Women After Index Pregnancy With and Without Placental Complications","CARDIOMOM","Inclusion Criteria:\n\n* Patients who participated in the BiSC (Barcelona Life Study Cohort), EuroPE (Randomized open-label control trial to evaluate if the incorporation of sFlt1\u002FPlGF ratio in the diagnosis and classification of PE improves maternal and perinatal outcomes in women with suspicion of the disease; PI16\u002F00375) and AngioCor (Cardiac dysfunction and remodeling in patients with preeclampsia regulated by antiangiogenic environment: clinical and experimental approach, PI19\u002F00702) cohort studies\n* Who have delivered within the previous 3-6 years.\n* Give written consent when invited to participate in this study protocol.\n\nExclusion Criteria:\n\n* Unwillingness to participate in this study\n* Probability of loss to follow-up.",{"count":439,"type":20},1260,"1 Day","In this project, the investigators aim to study how all these factors determine the cardiovascular status of a total of 1,800 mothers, 3 to 6 years after delivery. In addition, the investigators want to assess whether lifestyle and living conditions after childbirth may improve or worsen this imprint, since women often prioritize their families over themselves, making it more difficult to maintain a healthy lifestyle that could reduce their cardiovascular risk. Furthermore, the investigators will evaluate how environmental exposures influence their health, as well as explore potential strategies for prediction and prevention.\n\nThe goal is to develop an easy-to-use algorithm or test that allows women and their physicians to assess this risk, ideally in the form of a mobile app. Although predictive algorithms for cardiovascular health already exist, most have been developed using predominantly male or older populations, and none have taken into account pregnancy-related events or environmental exposure - both of which are key determinants of women's cardiovascular health.",[26,443,444],"Preeclampsia (PE)","Fetal Weight",[446,447,448],"preeclampsia","Cardiovascular Risk","app","2026-01-12",{"date":451,"type":31},"2026-01-21",{"date":453,"type":31},"2023-08-28",{"date":341,"type":20},{"name":456,"class":38},"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau",{"id":458,"slug":459,"hasResults":11,"nctId":460,"briefTitle":461,"officialTitle":462,"acronym":463,"eligibilityCriteria":464,"healthyVolunteers":80,"sex":16,"minAge":17,"maxAge":353,"enrollmentInfo":465,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":467,"conditions":468,"keywords":471,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":481,"lastUpdatePostDateStruct":482,"startDateStruct":484,"completionDateStruct":486,"leadSponsor":487,"locationsCount":183},"100611969","diet-and-cardiometabolism-in-rosario-100611969","NCT07247487","Diet and Cardiometabolism in Rosario","Comparative Analysis of Diet and Cardiometabolic Health in Individuals Following Vegan, Vegetarian, and Omnivorous Diets in the City of Rosario","DiCaMeR","Inclusion Criteria:\n\n* Adults aged 18 to 65 years.\n* Residence in the city of Rosario or surrounding areas.\n* Without major diseases.\n* BMI \\>18.5 and \\\u003C30.\n* Adherence to a vegan, vegetarian, or omnivorous diet for at least 1 consecutive year at the time of recruitment.\n\nExclusion Criteria:\n\n* Acute or chronic diseases (cancer, infections, heart disease, or others), gastrointestinal disorders affecting diet, diabetes mellitus, chronic kidney or liver disease, or any other condition that could affect study outcomes.\n* Food allergies or intolerances that substantially affect the individual's usual diet.\n* Pregnant or breastfeeding women.\n* High-performance athletes (\\>15 hours per week of high-intensity physical activity).\n* Use of medications that could affect study outcomes, including antihypertensives, lipid-lowering drugs, hypoglycemic agents, glucocorticoids, and anti-obesity drugs. Note: vitamin, mineral, or other dietary supplements are not exclusion criteria.\n* Problematic use of alcohol or other drugs.\n* Simultaneous participation in another clinical trial.\n* Inability (physical or psychological) to perform the procedures required by this study.\n* Blood transfusions within the last 3 months.",{"count":466,"type":20},105,"The DiCaMeR study is an observational, cross-sectional study aimed at evaluating the relationship between dietary patterns and cardiometabolic health in adults. The study includes adults following vegan, vegetarian, and omnivorous diets residing in Rosario, Argentina. Participants undergo comprehensive assessments including dietary intake, anthropometric measurements, body composition, blood pressure, grip strenght, and laboratory biomarkers related to cardiovascular and metabolic health. The main objective is to compare diet characteristics and cardiometabolic risk profiles across different dietary patterns, providing insights into the potential health benefits and risks associated with each dietary pattern.",[26,469,470],"Nutrition","Cardiometabolic Health Indicators",[472,473,474,475,476,477,478,469,479,480],"Vegan","Vegetarian","Plant-based","Cardiometabolic health","Cardiometabolism","Cardiovascular health","Diet","Dietary Patterns","Nutrients","2025-11-25",{"date":483,"type":31},"2025-12-03",{"date":485,"type":20},"2025-12-01",{"date":313,"type":20},{"name":488,"class":38},"Universidad del Centro Educativo Latinoamericano",{"id":490,"slug":491,"hasResults":11,"nctId":492,"briefTitle":493,"officialTitle":494,"acronym":495,"eligibilityCriteria":496,"healthyVolunteers":11,"sex":16,"minAge":112,"maxAge":497,"enrollmentInfo":498,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":500,"conditions":501,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":505,"lastUpdatePostDateStruct":506,"startDateStruct":508,"completionDateStruct":510,"leadSponsor":512,"locationsCount":39},"100612380","identification-of-asymptomatic-patients-at-very-high-cardiovascular-risk-contribution-of-a-strategy-based-on-carotid-and-coronary-explorations-compared-to-simple-risk-calculation-using-the-european-score-2-algorithm-idea-cvr-100612380","NCT07252830","Identification of Asymptomatic Patients at Very High Cardiovascular Risk: Contribution of a Strategy Based on Carotid and Coronary Explorations, Compared to Simple Risk Calculation Using the European \"SCORE 2\" Algorithm. (IDEA-CVR)","Identification of Asymptomatic Patients at Very High Cardiovascular Risk: Contribution of a Strategy Based on Carotid and Coronary Explorations, Compared to Simple Risk Calculation Using the European \"SCORE 2\" Algorithm.","IDEA-CVR","Inclusion Criteria:\n\n* Age \\> 40 years and \\\u003C 80 years referred to general cardiology consultation\n* LDL-C level \\> 1.6 g\u002FL, or LDL-C level \\> 1.3 g\u002FL with at least one associated major cardiovascular (CV) risk factor (RCF) (smoking, hypertension, diabetes).\n* Coronary artery reserve assessment and EDTSA performed in a day hospital\n\nExclusion Criteria:\n\n* Known or suspected carotid atherosclerotic disease\n* Significant ischemic heart disease known or suspected at the time of the initial consultation\n* Protected adult patient (patient under guardianship, curatorship, or other legal protection, deprived of liberty by judicial or administrative decision)\n* Opposition expressed by the patient to the use of their health data.\n* Patient may have limited understanding of the information sheet","80 Years",{"count":499,"type":20},1000,"To prevent myocardial infarction ( MI), coronary atheroma development by LDL-cholesterol deposition in the arterial wall is the basis. Since atheromatous plaques develop slowly before becoming symptomatic, their early detection in asymptomatic patients and the implementation of an effective strategy to prevent their progression constitute the most promising primary prevention strategy. In younger subjects, the main modifiable pro-atheromatous factors are smoking and an excessively high LDL-C level, partly genetically predetermined, but also favored by a diet too rich in saturated fats and a lack of physical activity. In the French national MI registry, the average age of patients is 62 years (Arch Cardiovasc Dis 2021 Oct;114(10):647-655). Half of MIs therefore occur at working age due to rupture of atheromatous plaques, which had developed during the months\u002Fyears preceding the acute event.\n\nAccording to the latest recommendations of the European Society of Cardiology (ESC) on CV prevention published in August 2021, the visualization of coronary or carotid atheromatous plaques justifies considering the patient as having atherosclerotic cardiovascular disease (ASCVD), and automatically places them in the \"very high CV risk\" category, with an LDL-cholesterol target of \\\u003C0.55 g\u002FL. However, these recommendations do not clearly define the criteria justifying the use of imaging in asymptomatic patients.\n\nIn current practice, CV risk stratification for asymptomatic patients with no prior CV disease is currently based on risk calculation using the European \"SCORE 2\" algorithm, available online. It allows the calculation of the absolute risk in % of occurrence of a fatal or non-fatal CV event (myocardial infarction, stroke) over 10 years.\n\nThe main objective of this study is to describe patients reclassified as \"very high CV risk\" following the detection of atheroma plaques formed in relation to their risk level estimated by SCORE2.",[502,503,504,26],"Myocardial Infarction","Atheroma","Cholesterol","2025-11-19",{"date":507,"type":31},"2025-11-28",{"date":509,"type":31},"2021-09-12",{"date":511,"type":20},"2026-01-20",{"name":513,"class":38},"Elsan",{"id":515,"slug":516,"hasResults":11,"nctId":517,"briefTitle":518,"officialTitle":518,"acronym":519,"eligibilityCriteria":520,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":521,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":523,"conditions":524,"keywords":527,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":532,"startDateStruct":534,"completionDateStruct":536,"leadSponsor":538,"locationsCount":39},"100608756","multimorbidity-and-cardiovascular-risk-factors-after-renal-transplant-100608756","NCT07205692","Multimorbidity and Cardiovascular Risk Factors After Renal Transplant","MCaRT","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* Capable of giving informed consent\n* In receipt of a single organ renal transplant and being followed up by UHDB as the referring team.\n\nExclusion Criteria:\n\n• Graft failure before return to follow up",{"count":522,"type":20},30,"Who can participate? Any adults over the age of 18 who have received a kidney transplant at the research centre are eligible for recruitment within the first month after transplant What does the study involve? The study involves observing and gathering data to understand how the health of people who receive a kidney transplant changes over the first year.\n\nIn particular the investigators are interested in the risk factors for heart disease and stroke, and how these change over the first year of transplant. The investigators are also interested in multiple health conditions, and how these impact patients after transplant.\n\nThere are no interventions but there will be measurements of diagnoses, risk factors for heart disease and stroke, and assessments of physical fitness Blood pressure, BMI, routine blood tests as well as assessing muscle and fat changes, how fit patients are and what new health conditions they have.\n\nWhat are the possible benefits and risks of participating? There is no active treatment or intervention, so there are no risks of benefits compared to normal care.\n\nWhere is the study run from? University Hospitals of Derby and Burton NHS trust, at the Royal Derby hospital Renal Department.\n\nWhen is the study starting and how long is it expected to run for? The study is expected to start 1\u002F9\u002F2025 and run for 2 years. Who is funding the study? The only costs of the study are funding for the staff member running the study, who is funded by the NIHR as an academic research fellow Who is the main contact? Dr Samuel Strain, Samuel.strain@nottingham.ac.uk",[525,26,526],"Kidney Transplant","Multimorbidity",[528,529,530,63],"multimorbidity","kidney transplant","renal transplant","2025-09-25",{"date":533,"type":31},"2025-10-03",{"date":535,"type":31},"2025-09-05",{"date":537,"type":20},"2027-08-01",{"name":539,"class":38},"University Hospitals of Derby and Burton NHS Foundation Trust",{"id":541,"slug":542,"hasResults":11,"nctId":543,"briefTitle":544,"officialTitle":545,"acronym":546,"eligibilityCriteria":547,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":548,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":550,"conditions":551,"keywords":558,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":563,"lastUpdatePostDateStruct":564,"startDateStruct":566,"completionDateStruct":568,"leadSponsor":570,"locationsCount":39},"100607391","cardiovascular-health-of-transgender-individuals-during-the-gender-affirming-pathway-100607391","NCT07187947","Cardiovascular Health of Transgender Individuals During the Gender-affirming Pathway","Cardiovascular Health of Transgender Individuals During the Clinical Gender-affirming Pathway","CV-TGD","Inclusion Criteria:\n\n* Diagnosis of gender incongruence\n* Age 18 years or older at the start of therapy\n* Undergoing gender-affirming (replacement or suppressive) hormone therapy with testosterone or with estradiol plus anti-androgens for at least 12 months\n* Provision of informed consent for study participation and for the processing of personal and sensitive data\n\nExclusion Criteria:\n\n* Any hormone therapy received before recruitment\n* History of cardiovascular events prior to the initiation of hormone therapy",{"count":549,"type":20},500,"Gender incongruence, now classified in ICD-11 as a \"marked and persistent incongruence between an individual's experienced gender and the gender assigned at birth,\" is managed in dedicated, multidisciplinary centres that coordinate psychological support with medical-surgical care.\n\nGender-affirming hormone therapy (GAHT) is central to this care pathway. In particular, masculinising GAHT for people assigned female at birth (AFAB) relies mainly on testosterone, and feminising or demasculinising GAHT for people assigned male at birth (AMAB) combines oestradiol with androgen-lowering agents such as cyproterone acetate or GnRH analogues (triptorelin, leuprorelin). In addition, Gender-affirming surgery (GAS) offers further individualised options: \"Top\" procedures- chest masculinisation for AFAB or breast augmentation for AMAB, and \"Bottom\" procedures\\*\\* such as hysterectomy with or without oophorectomy, phalloplasty or metoidioplasty for AFAB; orchiectomy or vaginoplasty for AMAB. Other ancillary interventions include facial feminisation or voice surgery.\n\nGAHT aims to suppress endogenous sex-hormone levels and secondary sex characteristics while inducing those consistent with the affirmed gender. Despite its widespread use, cardiovascular (CV) safety data are scant and largely observational. Sex-steroid receptors are ubiquitous in the vasculature and contribute to the sex-dimorphic patterns of CV risk seen in cisgender populations; GAHT is therefore biologically plausible as a modifier of CV outcomes in transgender people, yet robust evidence remains limited.\n\nCurrent literature suggests that AFAB individuals on testosterone exhibit an up to 2.66-fold higher composite CV risk than cisgender AFAB comparators. The most consistent changes are higher blood pressure and lower HDL cholesterol; clinically significant polycythaemia is uncommon and treatable. Instead, AMAB individuals on feminising therapy do not show a clearly increased overall CV risk compared with cisgender AMAB peers, though data are inconsistent. An observational study reported that within four months of GAHT initiation, systolic blood pressure rose by 2.6 mmHg in trans men and fell by 4 mmHg in trans women, with no diastolic change in either group.\n\nThe current evidence base is weakened by small cohorts, inadequate control groups, and reliance on surrogate biochemical markers rather than hard clinical endpoints. Many studies also overlook GAHT exposure altogether, hampering meaningful interpretation. Moreover, social determinants-mental-health burden, substance use, and healthcare inequities-compound CV risk but are seldom accounted for.\n\nKey unanswered questions include the long-term CV effects of GAHT, age-specific interactions with blood pressure and lipids, optimal therapeutic targets, and underlying mechanisms. Addressing these gaps demands rigorously designed, large-scale, prospective studies that actively involve transgender participants.\n\nIn summary, while GAHT is indispensable for gender affirmation, its cardiovascular implications-especially for AFAB individuals-warrant caution and systematic monitoring. Future evidence should inform tailored protocols that balance gender-affirming benefits against potential CV risks and integrate biomedical parameters with the broader social context impacting transgender health.",[552,26,553,554,555,556,557],"Gender Incongruence","Cardiovascular Disease Risk Factor","Cardiovascular Disease Acute","Cardiovascular Health Status","Cardiovascular Disease (CVD)","Cardiovascular Disease Prevention",[63,559,560,561,562],"transgender","GAHT","GAS","hormones","2025-09-19",{"date":565,"type":31},"2025-09-23",{"date":567,"type":31},"2025-07-18",{"date":569,"type":20},"2035-12-31",{"name":571,"class":38},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",{"id":573,"slug":574,"hasResults":11,"nctId":575,"briefTitle":576,"officialTitle":576,"acronym":4,"eligibilityCriteria":577,"healthyVolunteers":80,"sex":81,"minAge":17,"maxAge":83,"enrollmentInfo":578,"targetDuration":4,"studyType":51,"phases":580,"briefSummary":581,"conditions":582,"keywords":584,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":589,"lastUpdatePostDateStruct":590,"startDateStruct":592,"completionDateStruct":594,"leadSponsor":596,"locationsCount":39},"100605769","the-role-of-mobile-apps-in-promoting-cardiovascular-health-and-motivation-to-exercise-during-pregnancy-100605769","NCT07166822","The Role of Mobile Apps in Promoting Cardiovascular Health and Motivation to Exercise During Pregnancy","Inclusion Criteria:\n\n* Age: 18-45 years.\n* Pregnant women who are 20-24 weeks pregnant at enrollment\n* Sedentary, as defined by completing less than 90 minutes of exercise each week.\n* Generally healthy, uncomplicated pregnancies.\n* Free of physical limitations that may interfere with alterations in daily physical activity levels.\n* Single gestation.\n* Have a smartphone\n* Under the routine medical care of an obstetrician or certified nurse midwife during their current pregnancy.\n* Women speaking English.\n\nExclusion Criteria:\n\n* Physician diagnosed cardiovascular\u002F vascular complications (heart disease, high blood pressure, Raynaud's phenomenon etc.)\n* Physician diagnosed metabolic diseases (diabetes, hypothyroidism)\n* Musculoskeletal injuries (broken bones, back pain, ankle sprain, muscle pull, etc.)\n* Medications that may impact blood vessel function such as hypertension medication (Angiotensin converting enzyme inhibitor, Angiotensin receptor blocker, Calcium channel blocker, beta blocker), lipid lowering agents (statins), Nitrates, steroids, etc.\n* Complications associated with pregnancy that would be exacerbated by exercise such as lung disease, persistent spotting\u002Fbleeding or Placental Previa, premature labor, ruptured membranes, evidence of intrauterine growth restriction, pregnancy induced hypertension or pre-eclampsia, uncontrolled epileptic fits\u002Fseizures.\n* Smoking within the previous 3 months.",{"count":579,"type":20},50,[53],"The goal of this study is to determine the effectiveness of a mobile exercise app in improving cardiovascular health and motivation to exercise in pregnant women who are healthy, in their 2nd trimester, between 18-45 years age, and do not do exercise currently. The aims of this study are determine i) the effect of a mobile app (BumptUp) to increase motivation to exercise as assessed by questionnaire, and ii) the changes may occur in cardiovascular health outcomes such as increased percent Flow-Mediated Dilation (FMD), Heart Rate Variability (HRV), and decreased Pulse Wave Velocity (PWV) over an 8-week period of intervention. Researchers will compare this to pregnant women who are healthy, in their 2nd trimester, between 18-45 years age, and who will not be using the mobile app (BumptUp) for exercise. Participants who are in the experimental group will be given access to the mobile app (BumptUp) for 8 weeks. Both the control and experimental group will visit the lab for their baseline measurements (study visit 1), followed by two visits at 4 weeks (study visit 2) and 8 weeks (study visit 3) to have their heart rate variability, arterial stiffness (PWV), and vascular function (FMD) assessed. At each study visit, blood pressure, heart rate, height, and weight will also be measured. Additionally, at all three study visits, participants will fill out a questionnaire to determine motivation to exercise.",[26,583],"Exercise",[585,586,587,588],"pregnant","cardiovascular","mobile app","exercise","2025-09-03",{"date":591,"type":31},"2025-09-10",{"date":593,"type":20},"2025-09-15",{"date":595,"type":20},"2028-08-01",{"name":597,"class":38},"Old Dominion University",{"id":599,"slug":600,"hasResults":11,"nctId":601,"briefTitle":602,"officialTitle":602,"acronym":4,"eligibilityCriteria":603,"healthyVolunteers":80,"sex":81,"minAge":604,"maxAge":4,"enrollmentInfo":605,"targetDuration":4,"studyType":51,"phases":607,"briefSummary":608,"conditions":609,"keywords":610,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":613,"lastUpdatePostDateStruct":614,"startDateStruct":616,"completionDateStruct":617,"leadSponsor":619,"locationsCount":4},"100603489","the-effect-of-physical-activity-on-cardiovascular-disease-risk-awareness-and-self-worth-in-young-women-100603489","NCT07137182","The Effect of Physical Activity on Cardiovascular Disease Risk Awareness and Self-Worth in Young Women","Inclusion Criteria:\n\n* Being over 18 years of age\n* Voluntarily participating in the study\n* Being female\n\nExclusion Criteria:\n\n* Having any physical disability,\n* Having had an injury or accident,\n* Being pregnant or having recently given birth,\n* Having a cognitive impairment that would prevent completing the survey and maintaining communication,","18 Weeks",{"count":606,"type":20},60,[53],"The main purpose of this study was to reveal the self-worth perceptions of women who regularly participate in physical activity and to investigate the effect of physical activity on self-worth perception and cardiovascular risk awareness.",[26,359],[63,611,612],"physical activities","self worth","2025-08-22",{"date":615,"type":31},"2025-08-29",{"date":593,"type":20},{"date":618,"type":20},"2026-02-01",{"name":620,"class":38},"Karamanoğlu Mehmetbey University",{"id":622,"slug":623,"hasResults":11,"nctId":624,"briefTitle":625,"officialTitle":625,"acronym":4,"eligibilityCriteria":626,"healthyVolunteers":80,"sex":16,"minAge":17,"maxAge":138,"enrollmentInfo":627,"targetDuration":4,"studyType":51,"phases":629,"briefSummary":630,"conditions":631,"keywords":635,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":644,"lastUpdatePostDateStruct":645,"startDateStruct":647,"completionDateStruct":649,"leadSponsor":651,"locationsCount":183},"100582272","pulses-optimizing-pulse-consumption-for-cardiometabolic-health-100582272","NCT06861153","Pulses: Optimizing Pulse Consumption for Cardiometabolic Health","Inclusion Criteria:\n\n* ≥ 18 years old (with no upper age limit)\n* Currently consuming less than 1.5 cup-equivalents of pulses per week\n* Willing and able to participate in a 12-week dietary intervention focused on increased pulse consumption\n* Able to communicate in English and provide written informed consent\n* Assessed as suitable to participate in a nutrition intervention by the study dietitian or primary healthcare provider\n\nExclusion Criteria:\n\n* Individuals already consuming \\>150 minutes\u002Fweek of pulse-based dietary programming or otherwise regularly meeting high pulse intake benchmarks at baseline\n* Patients with food allergies or intolerances that preclude the consumption of pulses\n* Individuals who have not received clearance from their healthcare provider to make significant dietary modifications\n* Participants anticipating major changes in dietary habits due to elective surgery, planned relocation, or other lifestyle alterations during the study period (12 weeks)",{"count":628,"type":20},180,[53],"This randomized clinical trial aims to evaluate the effects of consuming two different doses of pulses (1.5 cups\u002Fweek or 3 cups\u002Fweek) in individuals with baseline intake below 1.5 cups\u002Fweek, compared to a control group receiving standard nutrition education based on the United States Department of Agriculture's (USDA) My Plate guidelines.\n\nThe main question the Pulses study aims to answer is:\n\n• What is the effect of increasing pulse consumption (in a dose-response manner) on specific cardiometabolic risk factors, including LDL-C, CRP, HBA1C, and blood pressure compared to standard nutrition education?\n\nFor secondary outcomes, this study aims to answer the following:\n\n• Does increased pulse consumption improve the following: overall serum lipid profile (Total cholesterol (TC), HDL-C, Triglycerides (TG), diet quality (measured by the Healthy Eating Index), and participants self-reported satisfaction with life (SWLS) and Satisfaction with Food-related Life (SWFoL).\n\nAll participants will attend biweekly classes and food demonstrations. The pulses groups will learn to prepare various pulse-based recipes, while the control group will receive guidance on preparing healthy meals following the USDA MyPlate recommendations.",[26,632,633,390,634],"Healthy Eating Index","HbA1c","CRP",[636,637,638,639,640,641,642,643],"pulses","pulse consumption","cardiometabolic health","dietary intervention","nutrition education","chronic disease prevention","healthy eating","dietary guidelines","2025-08-18",{"date":646,"type":31},"2025-08-19",{"date":648,"type":31},"2025-07-01",{"date":650,"type":20},"2028-09-01",{"name":652,"class":38},"University of Arizona"]